I
n their recent paper, Bowler and colleagues 1 used data from two large observational studies to investigate the question of whether use of e-cigarettes (ECs) by patients at risk of, or with, COPD impacted respiratory health outcomes. The conclusion was that the use of ECs was associated with poorer health outcomes. Unfortunately, the evidence presented in the paper is inadequate to provide much confidence in this conclusion.
First, the authors have relied on poorly constructed measures of EC use, which makes it hard to determine if the reported association is real or merely the result of misclassification error. The authors relied on ever and current use of ECs to define exposure. While these measures have value for documenting trends in EC use, they are not as helpful as in evaluating whether or not ECs contribute to smoking cessation or health outcomes since it is impossible to differentiate smokers who may have tried an EC from those who used them frequently for an extended period. Accounting for the frequency of EC use is important since previous studies have shown that daily use of ECs is related to a greater probability of smoking abstinence, which in turn would be expected to improve COPD health outcomes. [2] [3] [4] Another limitation of the study was failure to account for the type of EC used which is important since the type of EC used impacts nicotine delivery and the likely success smokers might have quitting 4 and likely varied over the six-year period of the study (2010) (2011) (2012) (2013) (2014) (2015) (2016) .
Finally, selection bias is an important potential confounder. While EC users were found to be more addicted and have a more prolonged exposure to cigarettes (i.e., pack/years), this would also be expected to be associated with poorer COPD outcomes. Controlling for baseline cigarette use attenuated the negative association with COPD outcomes suggesting that the patient's cigarette smoking history, not their use of ECs, could be the cause of poor COPD outcomes.
It is important to note that findings from this study differ from those of another study on the same topic. 5 Moreover, the potential risks and benefits of switching smokers to an alternative nicotine product were well articulated in the Lung Health Study. 6 We would strongly caution clinicians, public health experts, and policy-makers from reaching firm conclusions about the potential risks or benefits of EC use based on the studies reported to date.
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